P2RX7 and Stroke: Early treatment with a P2X7 receptor antagonist in stroke patients may prevent the activation of P2X7 receptors that are expressed on microglia/monocyte-derived macrophages in peri-lesion tissues, thus reducing the release of regional inflammatory cytokines and associated neuronal damage.